Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Simon

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
American Journal of Medical Genetics. Part A|November 26, 2010
HAX1 mutations causing severe congenital neuropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRIKaan Boztug, Xiao-Qi Ding, Hans Hartmann, et al.
The Journal of Pediatrics|June 25, 2017
Spinal Canal Involvement in NeuroblastomaToby Trahair, Stefania Sorrentino, Susan J Russell, et al.
Cell & Bioscience|September 24, 2022
Reliable assessment of telomere maintenance mechanisms in neuroblastomaAlina Meeser, Christoph Bartenhagen, Lisa Werr, et al.
JMIR Research Protocols|February 17, 2022
Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort StudyOliver Zolk, Annika von dem Knesebeck, Norbert Graf, et al.
Neuropediatrics|August 31, 2018
Dominant SCN2A Mutation Causes Familial Episodic Ataxia and Impairment of Speech DevelopmentWalid Fazeli, Kerstin Becker, Peter Herkenrath, et al.
Current Oncology (Toronto, Ont.)|November 10, 2022
Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg RegistryDanny Jazmati, Barbara Hero, Theresa M Thole-Kliesch, et al.
Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Frontiers in Endocrinology|July 5, 2022
Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma-Experiences From the GPOH-MET RegistryMichaela Kuhlen, Christina Pamporaki, Marina Kunstreich, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2023
Overcoming inter-observer planning variability in target volume contouring and dose planning for high-risk neuroblastoma - a European multicenter effort of the SIOPEN radiotherapy committeeDanny Jazmati, Lorenzo Brualla, Annemieke S Littooij, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
American Journal of Medical Genetics. Part A|November 26, 2010
HAX1 mutations causing severe congenital neuropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRIKaan Boztug, Xiao-Qi Ding, Hans Hartmann, et al.
The Journal of Pediatrics|June 25, 2017
Spinal Canal Involvement in NeuroblastomaToby Trahair, Stefania Sorrentino, Susan J Russell, et al.
Cell & Bioscience|September 24, 2022
Reliable assessment of telomere maintenance mechanisms in neuroblastomaAlina Meeser, Christoph Bartenhagen, Lisa Werr, et al.
JMIR Research Protocols|February 17, 2022
Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort StudyOliver Zolk, Annika von dem Knesebeck, Norbert Graf, et al.
Neuropediatrics|August 31, 2018
Dominant SCN2A Mutation Causes Familial Episodic Ataxia and Impairment of Speech DevelopmentWalid Fazeli, Kerstin Becker, Peter Herkenrath, et al.
Current Oncology (Toronto, Ont.)|November 10, 2022
Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg RegistryDanny Jazmati, Barbara Hero, Theresa M Thole-Kliesch, et al.
Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Frontiers in Endocrinology|July 5, 2022
Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma-Experiences From the GPOH-MET RegistryMichaela Kuhlen, Christina Pamporaki, Marina Kunstreich, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2023
Overcoming inter-observer planning variability in target volume contouring and dose planning for high-risk neuroblastoma - a European multicenter effort of the SIOPEN radiotherapy committeeDanny Jazmati, Lorenzo Brualla, Annemieke S Littooij, et al.
Pageof 13